IASLC WCLC 2020: CheckMate-743 shows that dual immunotherapy, nivolumab plus ipilimumab improves overall survival for patients with previously untreated mesothelioma
The combination of first-line nivolumab and ipilimumab demonstrated an improvement of overall survival for patients…